Аннотация:The effeciency and safety of continuing of EGFR-inhibition while switching the chemotherapy (CT) for patients with RAS wild-type metastatic colorectal cancer (mCRC) were analyzed. 20 patients were recruited. The therapy included: the 1st-line with FOLFOX-6+Cetuximab until progression, then FOLFIRI+ Cetuximab as the 2nd-line therapy. Response rate (RR), toxicity, PFS and OS were evaluated. The control group (20 patients) with 1st-line with FOLFOX-6+anti-EGFR drugand changing of chemotherapy on irinotecan-containing regimen with Bevaci-zumab after progression was used for the comparison of RR, PFS, and OS. OS in patients of study group was higher than in historical control: 29.0±3.4vs22.0±3.1 months, р=0.0458. Continued therapy anti-EGFR drugs in mCRC with wild-type RAS while switching chemotherapy deserves futher evaluation in additional studies in EGFR-dependent mCRC pts.
